Safety and efficacy of transdermal rotigotine for the treatment of fatigue and quality of life (QOL) in patients with Parkinson's disease.

Trial Profile

Safety and efficacy of transdermal rotigotine for the treatment of fatigue and quality of life (QOL) in patients with Parkinson's disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2015

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Aug 2015 New trial record
    • 18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top